Sugi Predict

Sugi Predict / Compounds / SCHEMBL27974

SCHEMBL27974

SCHEMBL27974

COC(=O)c1cc(F)c(F)cc1CBr

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 2/20 0.41
▸ LMNA P02545 4/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ SOS1 Q07889 1/20 0.38
▸ GAA P10253 4/20 0.38
▸ CA12 O43570 2/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ CA7 P43166 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ CA14 Q9ULX7 2/20 0.37
▸ PDK2 Q15119 1/20 0.37
▸ PDK4 Q16654 1/20 0.37
▸ KDM4E B2RXH2 6/20 0.37
▸ ALOX15 P16050 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20571368 0.88 SOS1 (0.44) DPP4LMNAMAPTHPGDALDH1A1
SCHEMBL30716891 0.88 SOS1 (0.44) DPP4LMNAMAPTHPGDALDH1A1
SCHEMBL15795869 0.88 SOS1 (0.41) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL364111 0.88 DPP4 (0.40) DPP4LMNAMAPTHPGDSMN1; SMN2
SCHEMBL31470564 0.87 CFTR (0.42) DPP4LMNAMAPTHPGDALDH1A1
SCHEMBL19691966 0.87 ALDH1A1 (0.44) LMNAMAPTHPGDALDH1A1GAA
SCHEMBL28015552 0.86 DPP4 (0.40) DPP4LMNAMAPTHPGDSMN1; SMN2
SCHEMBL25342892 0.86 ALDH1A1 (0.39) DPP4LMNAMAPTHPGDSMN1; SMN2
SCHEMBL31024674 0.86 ALDH1A1 (0.39) DPP4LMNAMAPTHPGDSMN1; SMN2
SCHEMBL16512963 0.83 ALDH1A1 (0.42) LMNAMAPTHPGDALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692092-A1 NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF Aliad Biopharma (KR) 2026-02-11 — — EP disclosed
CN-118812564-A EGFR-targeting proteolytic targeting chimeras, compositions and uses thereof 厦门宝太生物科技股份有限公司 2024-10-22 — — CN disclosed
WO-2024205377-A1 NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF 알리아드바이오파마 주식회사 2024-10-03 — — WO disclosed
CN-116888108-B Novel EGFR degradation agent 上海齐鲁制药研究中心有限公司 2024-04-19 — — CN disclosed
CN-116891502-A EGFR degrading agent 上海齐鲁制药研究中心有限公司 2023-10-17 — — CN disclosed
CN-116888108-A Novel EGFR degradation agent 上海齐鲁制药研究中心有限公司 2023-10-13 — — CN disclosed
US-20230091225-A1 Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof HINOVA PHARMACEUTICALS INC. (CN) 2023-03-23 — — US disclosed
WO-2022194269-A1 NOVEL EGFR DEGRADATION AGENT 上海齐鲁制药研究中心有限公司 2022-09-22 — — WO disclosed
EP-3957633-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2022-02-23 — — EP disclosed
CN-111825657-A Dual-function chimeric heterocyclic compound for targeted degradation of androgen receptor and application thereof 成都海创药业有限公司 2020-10-27 — — CN disclosed
US-20140200223-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2014-07-17 — — US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 — — US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 — — US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 — — US disclosed
EP-2406240-A2 INHIBITORS OF BETA-SECRETASE Vitae Pharmaceuticals, Inc. (US) 2012-01-18 — — EP disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 — — US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 — — US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 — — US disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 — — WO disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230091225-A1 Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof AR, ADRM1, PSMA1 DPP4 1985/4885LMNA 3055/4885MAPT 246/4885
US-20140200223-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 DPP4 113/4885LMNA 521/4885MAPT 78/4885
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 DPP4 113/4885LMNA 521/4885MAPT 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.